Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas
Open Access
- 12 April 2015
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 15 (1) , 272
Abstract
Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account for 25–30% of functioning pituitary adenomas, and bromocriptine (BRC) is the only commercially available DAs in China. However, tumors are resistant to therapy in 5–18% of patients. The exomes of six responsive prolactinomas and six resistant prolactinomas were analyzed by whole-exome sequencing. Using stringent variant calling and filtering parameters, ten somatic variants that were mainly associated with DNA repair or protein metabolic processes were identified. New resistant variants were identified in multiple genes including PRDM2, PRG4, MUC4, DSPP, DPCR1, RP1L1, MX2, POTEF, C1orf170, and KRTAP10-3. The expression of these genes was then quantified by real-time reverse-transcription PCR (RT–qPCR) in 12 prolactinomas and 3 normal pituitary glands. The mRNA levels of PRDM2 were approximately five-fold lower in resistant prolactinomas than in responsive tumors (p < 0.05). PRDM2 protein levels were lower in resistant prolactinomas than in responsive tumors, as determined by Western blotting and immunohistochemical analysis (p < 0.05). Overexpression of PRDM2 upregulated dopamine receptor D2 (D2DR) and inhibited the phosphorylation of ERK1/2 in MMQ cells. PRDM2 showed a synergistic effect with BRC on the inhibition of prolactin (PRL) secretion and MMQ cell viability, and low PRDM2 expression was associated with tumor recurrence. PRDM2 downregulation may play a role in dopamine-agonist resistance and tumor recurrence in prolactinomas.Keywords
This publication has 36 references indexed in Scilit:
- Resistant prolactinoma: Is it monoclonal or polyclonal?Indian Journal of Endocrinology and Metabolism, 2013
- DJ-1 Protects Dopaminergic Neurons against Rotenone-Induced Apoptosis by Enhancing ERK-Dependent MitophagyJournal of Molecular Biology, 2012
- Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) dysregulation in human malignant meningiomasOncogene, 2012
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- Effects of triptolide on RIZ1 expression, proliferation, and apoptosis in multiple myeloma U266 cellsActa Pharmacologica Sinica, 2010
- Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferaseCarcinogenesis, 2009
- Familial nasopharyngeal carcinoma in Hong Kong: epidemiology and implication in screeningFamilial Cancer, 2008
- Cloning, Expression, Purification and Crystallization of the PR Domain of Human Retinoblastoma Protein-Binding Zinc Finger Protein 1 (RIZ1)International Journal of Molecular Sciences, 2008
- Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistanceActa Neurochirurgica, 2005
- EFFECT OF BROMOCRIPTINE ON DNA SYNTHESIS, GROWTH AND HORMONE SECRETION OF SPONTANEOUS PITUITARY TUMOURS IN THE RATJournal of Endocrinology, 1981